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Inorganic polyphosphates (polyPs) are linear polymers of orthophosphate res-
idues linked by phosphoanhydride bonds similar to ATP. PolyPs are ubiqui-
tously distributed in nature from bacteria to mammalian cells where they
play multiple roles. Here we investigated intracellular localization of polyP
in cancer cell lines and tested the idea about the involvement of polyP in cell
growth.
To study PolyP localization and cellular levels we used DAPI-based method of
polyP staining. Experiments were performed using the following cell lines:
H1299 (lung cancer), U251 (glioma) and HEK293 as a control cell line. PolyP
was also visualized by immunocytochemistry with X-press tagged PolyP-
binding domain of exopolyphosphatase (PPX) and subsequent use of specific
antibodies. The role of PolyP in cancer cell proliferation was studied using
MTS proliferation assay. In these experiments endogenous PolyP was either
blocked by spermine, a polyamine with high PolyP-binding affinity, or depleted
by transient expression of PPX, an enzyme that specifically hydrolyzes PolyP
into orthophosphate.
PolyP levels were increased in glioma and lung cancer cells compare to
HEK 293 cells. Proliferation of lung carcinoma (H1299) cells was signif-
icantly inhibited when PolyP was blocked with spermine compare to con-
trol cells. However, proliferation of glioma cells (U251) was not affected
by spermine, even at high concentrations of this polyamine (60 mM), sug-
gesting a cancer type dependent effect or, involvement of divers mecha-
nisms of actions of PolyP in different cell types. These results suggest
that PolyP plays an important role in the regulation of proliferation of
cancer cells. Further investigation of PolyP contribution to cancer devel-
opment and progression may provide tools to detect, prevent and/or treat
cancer.
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Transient receptor potential of melastatin subfamily (TRPM7) channels has
been detected in the heart using molecular approaches. Recently we have
identified electrophysiologically the TRPM7-like current in native human
cardiomyocytes, and discovered that in ~1/3 of patients the current was
already activated at patch rupture. One of possible versions to explain
this phenomenon might be related with heart pathology such as ischemic
heart disease (IHD). To test this assumption we used cardiomyocytes
from right atrial appendages obtained from 77 adult patients with and
without IHD. With voltage-dependent and other ion channels inhibited,
TRPM7-like current was recorded using the whole-cell patch-clamp tech-
nique. The TRPM7-like current studied in 136 myocytes showed a marked
variation of outward (at þ80 mV) and inward (at 120 mV) current den-
sities ranging from 1.21 to 11.63 pA/pF and from 0.14 to 0.7 pA/pF,
respectively. The densities of TRPM7-like current did not correlate with
membrane capacitance or changes of biophysical properties. The TRPM7-
like current density was homogeneous for a given sample. We established
that higher TRPM7-like current values, at rupture and steady-state, were
recorded in cardiomyocytes obtained from patients with IHD (in pA/pF):
from 2.1450.12 to 5.3950.36 and from 0.3950.02 to 0.5550.03
for outward and inward current, respectively, versus without IHD (from
1.6850.22 to 4.0350.4, and from 0.2950.04 to 0.3950.04, respec-
tively, at þ80 mV and 120 mV). In addition, we tested influence of pH
that is major component of acute myocardial ischemia. Change of extracel-
lular pH from 7.4 to 4 markedly increased inward and outward magnitude
of TRPM7-like current, which again was more pronounced in cardiomyo-
cytes from patients with IHD. Our experiments revealed the enlarged
TRPM7-like current in atrial cardiomyocytes from patients with IHD, and
those cells were associated with the greatest response to the extracellular
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TRPC3, TRPC6 and TRPC7 are Ca2þ permeable non-selective cation channels
that have been implicated in cancer, cardiovascular, respiratory and kidney dis-
eases. In this study, CHO-K1 cells stably expressing human M3 muscarinic
acetylcholine receptors were infected with human TRPC3, TRPC6 or TRPC7
BacMam viruses and measured on QPatch and IonWorks Quattro automated
electrophysiology platforms. In the QPatch HT mode (single cell recording),
TRPC currents were rapidly activated by the muscarinic agonist carbachol
and then decayed irreversibly with a rank order of TRPC7>TRPC3>TRPC6.
In both HT and HTX (10 cells per well) mode there was large variation in cur-
rent levels between recordings. The lack of a good well-to-well comparison
means that QPatch has low suitability for TRPC screening assays. The Quattro
in PPC mode (64 cells per well), sufficiently normalised well-to-well variation
in carbachol activated TRPC currents to enable assays to be developed for
TRPC3 and TRPC6. The time delay on the Quattro between carbachol addition
and the first current measurement resulted in TRPC7 currents having almost
completely decayed so remaining currents were too small. The TRPC3 and
TRPC6 assays were validated with two recently described TRPC inhibitors.
Compound 8 [1] inhibited TRPC3 and TRPC6 currents with respective IC50
values of 1.15 0.2 mM and 245 7 nM (Mean5 SD, n=4-5). 2-(amino)-thia-
zole-4-carboxamide [2] inhibited TRPC3 and TRPC6 currents with respective
IC50 values of 1.45 1.1 and 0.95 0.2 mM (Mean5 SD, n=3). These values
are in good agreement with the published data.
This study demonstrates that TRPC3, TRPC6 and TRPC7 currents can be
measured on automated electrophysiology platforms. For TRPC channels,
the QPatch is suitable to profile channel biophysics whereas the Quattro is
more applicable for compound profiling.
[1] Patent WO2011/107474 A1.
[2] Patent WO2012/037349 A2.
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The Transient Receptor Potential Vanilloid 1 (TRPV1) and Ankyrin 1 (TRPA1)
ion channels belong to the TRP superfamily and are both integrators of a variety
of noxious stimuli.
Both channels are non selective cation channels which exert pleiotropic func-
tions in a variety of cells; more specifically they colocalize in primary sensory
neurons of the trigeminal, vagal and dorsal root ganglia (DRG).
TRPA1 is activated by a number of pungent and irritant reactive chemical
compounds including allyl isothiocyanate (mustard oil), cinnamaldehyde
(cinnamon oil), allicin (onions), carvacrol (oregano), polygodial (Tasmanian
pepper) and formaldehyde (formalin); all of these molecules elicit a painful
burning and a prickling sensation.
TRPV1 is activated by noxious stimuli including high temperature, pH, and
vanilloid compounds such as capsaicin. Moreover increased expression of
TRPV1 was detected in prostate, colon, and pancreatic cancers, revealing a
relevant role of TRPV1 as tumor suppressor.
In this context, we describe a new class of water soluble derivatives of lipoic
acid [1], which proved to block TRPA1 channels.
We screened a small molecule compounds library, by patch- clamp recordings
on culture cells expressing both the human and the mouse isoforms of TRPA1
channel, to compare the potency of each molecule towards well-known TRPA1
agonists (AITC, Menthol, cinnamaldehyde, oxaliplatin); selectivity studies
showed no appreciable block by these molecules of TRPM8, hERG and NaV
channels.
Finally we showed that a subgroup of these compounds is able to activate
TRPV1 channels, suggesting interesting applications of our molecules for the
treatment of many diseases.
[1] Nativi C., Gualdani R. et al. (2013) ‘A TRPA1 antagonist reverts
oxaliplatin-induced hyperalgesia’. Scientific Reports, 3, 1-10.
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